Rhumbline Advisers Adaptimmune Therapeutics PLC Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 19,160 shares of ADAP stock, worth $11,304. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,160
Previous 16,721
14.59%
Holding current value
$11,304
Previous $16,000
12.5%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ADAP
# of Institutions
83Shares Held
150MCall Options Held
60.8KPut Options Held
5.8K-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$22.2 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$16.2 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$10.1 Million1.24% of portfolio
-
Baillie Gifford & CO16.8MShares$9.9 Million0.01% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR13.3MShares$7.85 Million0.46% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $96.4M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...